Survey

How are the Trump tariffs affecting you? Take our survey and let us know.

Munich - Delayed Quote EUR

Tvardi Therapeutics Inc. R (69C.MU)

16.88

+0.74

+(4.56%)

At close: April 24 at 8:23:53 AM GMT+2

Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split

STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”), today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock and reduction in the total number of authorized shares of its common stock from 200,000,000 to 16,666,667 will be effective as of 5:00 p.m. Eastern Time on Monday, December 30, 2024. The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market o

GlobeNewswire 3 months ago

CARA
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has recently completed an approximately $28 million private financing, which, together with Tvardi’s existing cash and Cara’s anticipated cash balance, is expected to fund the combined company into the second half of 2026 Tvardi anticipates reporting topline data in the second half of 2025 from two Phase 2 clinical programs utili

GlobeNewswire 4 months ago

CARA
Tessera gets sickle cell funding; Corvus shares slide on eczema data

The Bill & Melinda Gates Foundation will invest up to $50 million in Tessera’s in vivo sickle cell therapy. Elsewhere, Cara agreed to a reverse merger and J&J had a drug application rejected.

BioPharma Dive 4 months ago

JNJ

CRVS

SRPT
Cara Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Cara Therapeutics ( NASDAQ:CARA ) Third Quarter 2024 Results Key Financial Results Revenue: US$2.56m (down 48% from 3Q...

Simply Wall St. 5 months ago

CARA
Cara: Q3 Earnings Snapshot

CARA) on Thursday reported a loss of $12.5 million in its third quarter. The Stamford, Connecticut-based company said it had a loss of 23 cents per share. Losses, adjusted for asset impairment costs, came to 15 cents per share.

Associated Press Finance 5 months ago

CARA
Cara: Q2 Earnings Snapshot

On a per-share basis, the Stamford, Connecticut-based company said it had a loss of 37 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 29 cents per share.

Associated Press Finance 8 months ago

CARA
Cara Therapeutics Announces Exploration of Strategic Alternatives

Piper Sandler & Co. to act as financial advisorSTAMFORD, Conn., July 11, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that it has engaged Piper Sandler & Co. to act as its financial advisor for the process of exploring and reviewing strategic alternatives. “We are committed to evaluating a range of strategic options to maximize value for our shareholders,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. “As part of this effo

GlobeNewswire 9 months ago

CARA
Chipotle, McDonald's initiated: Wall Street's top analyst calls

Chipotle, McDonald's initiated: Wall Street's top analyst calls

The Fly 10 months ago

CMG

CARA

MCD
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica

– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the

GlobeNewswire 10 months ago

CARA
Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of -47.37% and 5.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 11 months ago

CARA
Cara Therapeutics Reports First Quarter 2024 Financial Results

Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24STAMFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the first quarter ended March 31, 2024. “Our notalgia paresthetic

GlobeNewswire 11 months ago

CARA
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024

STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will report first quarter 2024 financial results on Monday, May 13, 2024, after the U.S. markets close. The press release will be available under “Press Releases” in the Investors section of the Company’s website at www.CaraTherapeutics.com. Abo

GlobeNewswire 11 months ago

CARA

Performance Overview

Return	69C.MU	S&P 500 (^GSPC)
YTD	-0.71%	-6.75%
1-Year	-0.71%	+8.15%
3-Year	-0.71%	+28.40%